Suppr超能文献

一名患者从腹膜透析转为血液透析后出现血性腹水。

Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis.

作者信息

Pollock Carol A

机构信息

Department of Medicine, Royal North Shore Hospital, Kolling Institute, University of Sydney, St. Leonards, Australia.

出版信息

Semin Dial. 2003 Sep-Oct;16(5):406-10. doi: 10.1046/j.1525-139x.2003.16088.x.

Abstract

A 65-year-old woman with end-stage renal disease (ESRD) presented with bloody ascites. She had been maintained on peritoneal dialysis (PD) for 7 years and had eight episodes of peritonitis. She was eventually transferred to hemodialysis (HD) because of ultrafiltration failure. This was associated with "high" peritoneal transport by peritoneal equilibration test (PET). A period of "peritoneal rest" did not improve PET results. Within a year of transfer to HD, ascites developed, which was hemorrhagic upon evaluation. A computed tomography (CT) scan suggested encapsulating sclerosing peritonitis, which was confirmed upon peritonoscopy. The patient was treated with prednisone and tamoxifen. Encapsulating peritoneal sclerosis (EPS) is a devastating complication of PD. Although it is rare and its development often unpredictable, this case demonstrates several clinical features commonly observed in the condition. These include more than 6 years on PD, a high transporter status, recurrent peritonitis, and the development of blood-stained dialysis effluent (or ascites if PD has been discontinued, as was the case in this patient). The initial presentation is often incipient with vague abdominal pain. Symptoms are progressive, however, and EPS has a high mortality rate, with most patients dying within 1 year of diagnosis, usually from malnutrition and sepsis. Treatment options include systemic immunosuppression and regular peritoneal irrigation after transfer to HD. Response to treatment is more likely to occur in the early inflammatory stage of EPS, when symptoms are nonspecific and imaging is relatively normal. Hence a high degree of suspicion for the diagnosis should be present in patients "at risk" of this condition, as early diagnosis is essential if progressive encapsulation of the abdominal viscera is to be prevented.

摘要

一名65岁的终末期肾病(ESRD)女性患者出现血性腹水。她接受腹膜透析(PD)治疗已达7年,发生过8次腹膜炎。最终因超滤失败转至血液透析(HD)。这与腹膜平衡试验(PET)显示的“高”腹膜转运有关。一段时期的“腹膜休息”并未改善PET结果。转至HD治疗不到一年,腹水出现,经评估为出血性。计算机断层扫描(CT)提示为包裹性硬化性腹膜炎,经腹腔镜检查得以证实。患者接受了泼尼松和他莫昔芬治疗。包裹性腹膜硬化(EPS)是PD的一种严重并发症。尽管它很罕见且其发展往往不可预测,但该病例展示了这种病症常见的几个临床特征。这些特征包括PD治疗超过6年、高转运状态、复发性腹膜炎以及出现血性透析流出液(如果已停止PD治疗,则为腹水,本病例即如此)。最初表现往往为轻微腹痛。然而症状会逐渐加重,且EPS死亡率很高,大多数患者在诊断后1年内死亡,通常死于营养不良和败血症。治疗选择包括全身免疫抑制以及转至HD治疗后定期进行腹膜灌洗。在EPS的早期炎症阶段,当症状不具特异性且影像学相对正常时,对治疗的反应更有可能出现。因此,对于这种病症“高危”患者应高度怀疑其诊断,因为若要防止腹腔脏器的渐进性包裹,早期诊断至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验